Elastography ROI for Australian Private Clinics

Adding a new diagnostic service to your practice is a capital decision. For liver elastography, the numbers work — but only if you model them correctly. This guide walks through the key variables: scan volume, fee setting, device cost, throughput efficiency, and payback period.

We'll also show why the device economics are often competitive or better for guided elastography than for traditional blind systems when capital, probes, service, and failed-scan rates are considered together.

The Revenue Model

Liver elastography is a billable scan. In Australian private practice, scan fees typically range from $120 to $200 per patient, with many clinics settling around $150. Volume is the primary lever.

These are scan revenue figures — your net margin after staffing, consumables, and overhead will vary by practice structure.

The Device Cost Difference

This is where the choice of system matters significantly. Traditional blind elastography systems often land around $100,000+ AUD once you include typical new-unit capital, XL probe needs for BMI >30 cohorts, and distributor variability. Guided elastography systems supplied through Elastography Australia are typically quoted in the ~$80,000–$90,000 AUD range — modestly lower capital than many comparable new FibroScan deployments, with a single universal probe and lighter mandatory service overhead in most configurations.

That capital gap is smaller than older 'half price' talking points suggested, but when XL probes, annual service, failed scans, and billing pathways are modelled together, guided systems frequently still deliver a faster effective payback. At 15 scans per week and ~$150 gross scan revenue, many clinics see roughly 9–14 months to recover indicative device capital for guided TE versus somewhat longer timelines for higher TCO blind systems — exact results depend on your fee setting and operating costs.

What Drives Volume?

Scan volume doesn't arrive on day one. The practices that build to 15+ scans per week typically do so through:

• GP referral relationships — many GP practices now have their own elastography but still refer out complex cases, high-BMI patients, and hepatitis B monitoring.

• Hepatologist and gastroenterologist networks — specialists who trust your scan quality and reporting will send consistent volume.

• MAFLD and diabetes patient populations — both conditions have high prevalence in Australia and both warrant regular liver fibrosis surveillance. A practice serving these populations has a natural pipeline.

• MBS-funded pathways — indeterminate FIB-4 results, which trigger guideline-recommended elastography, represent an ongoing source of scan demand that grows as more GPs adopt FIB-4 screening.

Throughput: Why Scan Time Matters

For an imaging centre billing by throughput, the scan time difference between guided and blind elastography is commercially meaningful. Guided elastography systems achieve a median exam time of approximately 2 minutes vs approximately 5 minutes for traditional systems. That's nearly 3 minutes per scan — which adds up to meaningful throughput gains at scale.

At 20 scans per day, that's approximately 60 minutes of recovered capacity per day, or one additional scan slot every 3 minutes freed. For a high-volume centre, this can translate to additional scan revenue without additional room time.

The Obese Patient Factor

BMI >30 patients represent a growing proportion of Australian patients presenting for liver assessment. Traditional blind elastography systems show elevated failure rates in this population with the M probe — some studies report failure rates of 20–25% in high-BMI cohorts.

Failed scans are not billable scans. Every failed attempt at a $150 scan is $150 of foregone revenue plus wasted staff time. Guided elastography's higher success rate in obese patients — published cohorts report ~96.5% overall success — directly protects revenue integrity in this growing patient segment.

Leasing vs Outright Purchase

At indicative ~$80,000–$90,000 AUD capital, many practices still find outright purchase workable compared to leasing, particularly when equipment finance spreads payments across clinical revenue. For practices that prefer to preserve capital, equipment finance arrangements are available — speak with your accountant about the depreciation and tax implications of medical equipment acquisition in Australia.

Elastography Australia also offers demonstration loan programmes for practices wanting to trial the system before committing. Contact us to discuss.